NO782129L - Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser

Info

Publication number: NO782129L
Authority: NO; Norway
Prior art keywords: compound; formula; compounds; procedure; active compounds
Prior art date: 1977-06-20

Application number

NO782129A

Other languages

English (en)

Norwegian (no)

Inventor

Barbara Nunn

Keith Howard Baggaley

Original Assignee

Beecham Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-06-20

Filing date

1978-06-19

Publication date

1978-12-21

1978-06-19 Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd

1978-12-21 Publication of NO782129L publication Critical patent/NO782129L/no

Links

150000001875 compounds Chemical class 0.000 title claims description 49
238000000034 method Methods 0.000 title claims description 10
230000001225 therapeutic effect Effects 0.000 title description 2
238000002360 preparation method Methods 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
239000000460 chlorine Substances 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 2
LEHPTDUMTDRRKM-UHFFFAOYSA-N 2-(3-piperidin-1-ylpropyl)-1,2-benzothiazol-3-one Chemical compound S1C2=CC=CC=C2C(=O)N1CCCN1CCCCC1 LEHPTDUMTDRRKM-UHFFFAOYSA-N 0.000 claims 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
239000003937 drug carrier Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
210000004623 platelet-rich plasma Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
239000000725 suspension Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000003146 anticoagulant agent Substances 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 4
239000002585 base Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
206010003178 Arterial thrombosis Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000002744 anti-aggregatory effect Effects 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
230000035602 clotting Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000000047 product Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
238000011282 treatment Methods 0.000 description 3
KANAPVJGZDNSCZ-UHFFFAOYSA-N 1,2-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)N=CC2=C1 KANAPVJGZDNSCZ-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000004931 aggregating effect Effects 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
-1 alkali metal salt Chemical class 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
DSFZYLCRXIWFFW-UHFFFAOYSA-N 2-[(2-carbonochloridoylphenyl)disulfanyl]benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(Cl)=O DSFZYLCRXIWFFW-UHFFFAOYSA-N 0.000 description 1
JMUCXULQKPWSTJ-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCCC1 JMUCXULQKPWSTJ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
238000004821 distillation Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000001 effect on platelet aggregation Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000001631 vena cava inferior Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

NO782129A 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser NO782129L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB2559977		1977-06-20

Publications (1)

Publication Number	Publication Date
NO782129L true NO782129L (no)	1978-12-21

Family

ID=10230306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO782129A NO782129L (no)	1977-06-20	1978-06-19	Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser

Country Status (16)

Country	Link
US (1)	US4186203A (fr)
EP (1)	EP0000254B1 (fr)
JP (1)	JPS549283A (fr)
AR (1)	AR216675A1 (fr)
AU (1)	AU516003B2 (fr)
CA (1)	CA1098447A (fr)
DE (1)	DE2860750D1 (fr)
DK (1)	DK275478A (fr)
ES (3)	ES470977A1 (fr)
FI (1)	FI781956A7 (fr)
IE (1)	IE46937B1 (fr)
IL (1)	IL54956A0 (fr)
IT (1)	IT7849941A0 (fr)
NO (1)	NO782129L (fr)
NZ (1)	NZ187628A (fr)
ZA (1)	ZA783508B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58177915A (ja) *	1982-04-12	1983-10-18	Green Cross Corp:The	抗血栓剤
FR2583046B1 (fr) *	1985-06-05	1987-07-17	Cird	Alkyl ou aralkyl thio-2 cycloalkene-1 carboxamides-1 et leurs sulfoxydes, leurs procedes de preparation et leur application a la synthese de tri et tetramethylene-4,5 isothiazoline-4, ones-3
DE3617976A1 (de) *	1986-05-28	1988-01-14	Alter Sa	1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten
CA1335289C (fr) *	1987-10-26	1995-04-18	Fujio Antoku	Derives piperidinylbenzisoxazole, leur production et leur utilisation pharmaceutique
JP2581739Y2 (ja) *	1990-12-29	1998-09-24	箱竹株式会社	多目的ラック

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH395094A (de) *	1960-03-24	1965-07-15	Wander Ag Dr A	Verfahren zur Herstellung von 6-Chlor-benzisothiazolon
DE1147947B (de) *	1961-07-25	1963-05-02	Knoll Ag	Verfahren zur Herstellung neuer 1, 2-Benzisothiazolone
US3661974A (en) *	1970-04-27	1972-05-09	Sherwin Williams Co	2-carbalkoxy-phenyl sulfenamides
NZ182325A (en) *	1975-11-18	1979-03-16	Beecham Group Ltd	2-substituted-1,2-benzisothiazol-3-ones
DE2602643C2 (de) *	1976-01-24	1984-12-20	Bayer Ag, 5090 Leverkusen	1,2-Benzisothiazolinone-3, Verfahren zu ihrer Herstellung sowie Arzneimittel
ZA776857B (en) *	1976-12-04	1978-09-27	Beecham Group Ltd	Heterocyclic compounds

1978
- 1978-06-15 EP EP78300050A patent/EP0000254B1/fr not_active Expired
- 1978-06-15 DE DE7878300050T patent/DE2860750D1/de not_active Expired
- 1978-06-19 FI FI781956A patent/FI781956A7/fi not_active Application Discontinuation
- 1978-06-19 US US05/917,069 patent/US4186203A/en not_active Expired - Lifetime
- 1978-06-19 DK DK275478A patent/DK275478A/da unknown
- 1978-06-19 NO NO782129A patent/NO782129L/no unknown
- 1978-06-19 AR AR272657A patent/AR216675A1/es active
- 1978-06-19 IE IE1226/78A patent/IE46937B1/en unknown
- 1978-06-19 ZA ZA00783508A patent/ZA783508B/xx unknown
- 1978-06-19 CA CA305,704A patent/CA1098447A/fr not_active Expired
- 1978-06-20 IL IL7854956A patent/IL54956A0/xx unknown
- 1978-06-20 IT IT7849941A patent/IT7849941A0/it unknown
- 1978-06-20 AU AU37294/78A patent/AU516003B2/en not_active Expired
- 1978-06-20 ES ES470977A patent/ES470977A1/es not_active Expired
- 1978-06-20 NZ NZ187628A patent/NZ187628A/xx unknown
- 1978-06-20 JP JP7478278A patent/JPS549283A/ja active Pending
1979
- 1979-03-15 ES ES478685A patent/ES478685A1/es not_active Expired
- 1979-03-15 ES ES478686A patent/ES478686A1/es not_active Expired

Also Published As

Publication number	Publication date
US4186203A (en)	1980-01-29
IE781226L (en)	1978-12-20
FI781956A7 (fi)	1978-12-21
IT7849941A0 (it)	1978-06-20
AR216675A1 (es)	1980-01-15
ES470977A1 (es)	1979-10-01
CA1098447A (fr)	1981-03-31
DE2860750D1 (en)	1981-09-17
IE46937B1 (en)	1983-11-02
DK275478A (da)	1978-12-21
JPS549283A (en)	1979-01-24
AU516003B2 (en)	1981-05-14
NZ187628A (en)	1981-01-23
ES478686A1 (es)	1979-07-01
AU3729478A (en)	1980-01-03
ZA783508B (en)	1979-06-27
ES478685A1 (es)	1979-07-01
EP0000254A1 (fr)	1979-01-10
EP0000254B1 (fr)	1981-06-10
IL54956A0 (en)	1978-08-31

Publication	Publication Date	Title
DK170166B1 (da)	1995-06-06	N-(endo-9-methyl-9-azabicyclo(3,3,1)non-3-yl)-1-m ethylindazol-3-carboxamid med 5-HT-antagonist-aktivitet, farmaceutiske præparater indeholdende forbindelsen, en fremgangsmåde til fremstilling af forbindelsen samt dens anvendelse som et farmaceutisk middel
KR100263414B1 (ko)	2001-04-02	티에노 [3,2-b] 피리딘 유도체
JP6533159B2 (ja)	2019-06-19	ニトロキシル供与体を含む医薬組成物
NO763922L (fr)	1977-05-20
CZ283619B6 (cs)	1998-05-13	Použití derivátů kyseliny benzoové pro výrobu farmaceutických prostředků, deriváty kyseliny benzoo vé, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
KR20170095845A (ko)	2017-08-23	디히드로인돌리지논 유도체
IE60000B1 (en)	1994-05-18	Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
FI112866B (fi)	2004-01-30	Menetelmä uusien, terapeuttisesti käyttökelpoisten, heksahydro-8-hydroksi-2,6-metano-2H-kinolitsiinien amidijohdannaisten valmistamiseksi sekä menetelmässä käytettävät välituotteet
JP3408546B2 (ja)	2003-05-19	抗喘息剤
WO2008005352A2 (fr)	2008-01-10	Préparations en doses solides d'un antagoniste des récepteurs de la thrombine
EP0000254B1 (fr)	1981-06-10	2-(Gamma-(1-piperidinyl)propyl)1,2-benzisothiazole 3-one antithrombotique, ses sels d'acides pharmaceutiquement acceptables, leur préparation et leurs compositions
EP0682947A1 (fr)	1995-11-22	Médicament pour le traitement thérapeutique prophylactique des maladies causées par une hyperplasie des cellules musculaires lisses
DE2718707A1 (de)	1977-11-10	Isothiazolopyridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
EP0555042B1 (fr)	1996-04-03	Composition pharmaceutique pour inhiber l'aggregation de plaques thrombocytes
AU7768091A (en)	1991-11-11	Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
JP2997894B2 (ja)	2000-01-11	循環器系疾患の予防及び治療剤
JPS6258335B2 (fr)	1987-12-05
DK170234B1 (da)	1995-07-10	Hydrochloridhydrat af Endo-4-amino-5-chlor-2-methoxy-N-(1'-azabicyclo-[3.3.1]-non-4'-yl)-benzamid, fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende forbindelsen samt anvendelse af forbindelsen
US4182768A (en)	1980-01-08	Prophylaxis or treatment of thromboses and inhibition of platelet aggregation in human blood
PT91198B (pt)	1995-03-01	Processo para a preparacao de derivados antiulcera da (alquilditio) quinolina
EP0001503B1 (fr)	1981-01-07	Compositions à effet antithrombotique contenant des benzisothiazolones
US4164579A (en)	1979-08-14	Hydroxythiazolidine-2-thiones
JP2798005B2 (ja)	1998-09-17	平滑筋細胞増殖に起因する疾患の治療・予防剤
KR860000768B1 (ko)	1986-06-23	치환된 푸로푸라논 유도체의 제조방법
UA44249C2 (uk)	2002-02-15	3-алкоксикарбонілтіадіазинони, спосіб їх одержання, фармацевтична композиція, спосіб одержання фармацевтичних композицій